Specifications Manual for Joint Commission National Quality Measures (v2020B)
Posted: 2/5/2020
Home » Reason for Oral Factor Xa Inhibitor

Release Notes:
Data Element
Version 2020B

Name:Reason for Oral Factor Xa Inhibitor
Collected For: STK-1
Definition:Documentation why Oral Factor Xa Inhibitor was administered for VTE prophylaxis.
Question:Is there physician/APN/PA or pharmacist documentation why Oral Factor Xa Inhibitor was administered for VTE prophylaxis?
Format:
Length:1
Type:Alphanumeric
Occurs:1
Allowable Values:

Y (Yes) There is physician/APN/PA or pharmacist documentation why Oral Factor Xa Inhibitor was administered for VTE Prophylaxis.

N (No) There is no physician/APN/PA or pharmacist documentation why Oral Factor Xa Inhibitor was administered for VTE Prophylaxis, OR unable to determine from the medical record documentation.
Notes for Abstraction:
  • The only acceptable reasons are identified in the list of inclusions. No other reasons will be accepted.
  • History of atrial fibrillation/flutter or current finding of atrial fibrillation/flutter, select “Yes.”
  • If the patient has a history of previous strokes and/or taking an Oral Factor Xa Inhibitor prior to hospital arrival, select "Yes".
  • History of hip or knee replacement surgery, select “Yes.”
  • When conflicting information is documented in the medical record, select “Yes.”
  • History of treatment for venous thromboembolism or current treatment for venous thromboembolism, select “Yes.”
Suggested Data Sources: PHYSICIAN/APN/PA or PHARMACIST DOCUMENTATION ONLY IN THE FOLLOWING ONLY ACCEPTABLE SOURCES:
  • Anesthesia record
  • Consultation notes
  • Emergency Department record
  • History and physical
  • Operative Note
  • Physician orders
  • Progress notes
  • Risk assessment form
  • Transfer sheet
Additional Notes:

Guidelines for Abstraction:
Inclusion Exclusion
This list is all inclusive
  • AF
  • A-fib
  • Atrial fibrillation
  • Atrial flutter
  • History of any remote episode of documented atrial fibrillation or flutter except within 8 weeks following CABG
  • PAF
  • Paroxysmal atrial fibrillation
  • Partial hip arthroplasty
  • Partial hip replacement
  • Persistent atrial fibrillation
  • Stroke prevention / history of stroke
  • THR
  • TKR
  • Total hip arthroplasty
  • Total hip replacement
  • Total knee arthroplasty
  • Total knee replacement
  • Treatment of venous thromboembolism

  • Hip fracture
  • History of atrial fibrillation or flutter that terminated within 8 weeks following CABG
  • History of transient and entirely reversible episode of documented atrial fibrillation or flutter due to thyrotoxicosis
  • PAC
  • Paroxysmal atrial tachycardia
  • Paroxysmal supraventricular tachycardia
  • PAT
  • Premature atrial contraction
  • PST

Reason for Oral Factor Xa Inhibitor
CPT® only copyright 2019 American Medical Association. All rights reserved.
Specifications Manual for Joint Commission National Quality Measures (v2020B)
Discharges 07-01-20 (3Q20) through 12-31-20 (4Q20)

LICENSE FOR USE OF CURRENT PROCEDURAL TERMINOLOGY, FOURTH EDITION (“CPT®”)

CPT® only copyright 2019 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.

You, your employees and agents are authorized to use CPT® only as contained in The Joint Commission performance measures solely for your own personal use in directly participating in healthcare programs administered by The Joint Commission. You acknowledge that the American Medical Association (“AMA”) holds all copyright, trademark and other rights in CPT®.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT® for resale and/or license, transferring copies of CPT® to any party not bound by this Agreement, creating any modified or derivative work of CPT®, or making any commercial use of CPT®. License to use CPT® for any use not authorized herein must be obtained through the American Medical Association, Intellectual Property Services, AMA Plaza, 330 North Wabash Avenue, Suite 39300, Chicago, Illinois 60611-5885. Applications are available at the American Medical Association Web site, www.ama- assn.org/go/cpt.

U.S. Government Rights This product includes CPT® which is commercial technical data, which was developed exclusively at private expense by the American Medical Association, 330 North Wabash Avenue, Chicago, Illinois 60611. The American Medical Association does not agree to license CPT® to the Federal Government based on the license in FAR 52.227-14 (Data Rights - General) and DFARS 252.227-7015 (Technical Data - Commercial Items) or any other license provision. The American Medical Association reserves all rights to approve any license with any Federal agency.

Disclaimer of Warranties and Liabilities. CPT® is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT®, and the (AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this product is with The Joint Commission, and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this product.

This Agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this Agreement.

Should the foregoing terms and conditions be acceptable to you, please indicate your agreement and acceptance by clicking below on the button labeled “accept”.

^